Authors
Latest Article
Gloomy Number Forecast
Robert Giugliano, MD, is a senior investigator with the TIMI Study Group, staff physician in the Cardiovascular Division at Brigham and Women’s Hospital, and associate professor of medicine at Harvard Medical School. Dr. Giugliano’s areas of research interest include novel antithrombotic, fibrinolytic agents, and lipid-lowering therapies, and patient outcomes following Acute Coronary Syndromes. He has authored more than 200 articles and chapters, and delivered hundreds of lectures. Dr. Giugliano is the principal investigator for the ENGAGE-AF TIMI 48 trial, and a member of the Operations Committees and lead TIMI investigator for the IMPROVE-IT, FOURIER, and EARLY ACS trials.
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
What Comes Next for Berobenatide? VESPER-3 and Phase 3 Expectations, With John Buse, MD, PhD
3
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
4
Ketone Monitoring in Diabetes: Making The Case For When and How to Test
5

